Rockwell Medical, Inc. (RMTI) Financial Ratios
29 years of historical data (1997–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: 21.96
30Y Low22.0·High61.9
P/FCF
N/A
—
5yr avg: 19.86
30Y Low19.9·High119.1
P/B Ratio
↓
0.65
↓-84% vs avg
5yr avg: 4.14
30Y Low0.7·High15.2
ROE
↑
-15.3%
↓+84% vs avg
5yr avg: -93.5%
30Y Low-224%·High6%
Debt/EBITDA
N/A
—
5yr avg: 4.85
30Y Low1.6·High4.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RMTI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Rockwell Medical, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $26M | $30M | $63M | $44M | $10M | $38M | $76M | $149M | $119M | $296M | $333M |
| Enterprise Value | $23M | $27M | $61M | $49M | $16M | $54M | $52M | $141M | $97M | $287M | $315M |
| P/E Ratio → | -4.46 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.38 | 0.43 | 0.62 | 0.53 | 0.14 | 0.62 | 1.23 | 2.42 | 1.88 | 5.16 | 6.24 |
| P/B Ratio | 0.65 | 0.81 | 1.94 | 2.07 | 0.71 | 15.17 | 2.24 | 7.32 | 4.38 | 8.99 | 6.28 |
| P/FCF | — | — | 19.86 | — | — | — | — | — | — | — | — |
| P/OCF | — | — | 15.08 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RMTI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.39 | 0.60 | 0.58 | 0.22 | 0.87 | 0.83 | 2.30 | 1.53 | 5.02 | 5.92 |
| EV / EBITDA | — | — | 21.96 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 79.11 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | 19.19 | — | — | — | — | — | — | — | — |
RMTI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Rockwell Medical, Inc. earns an operating margin of -6.8%. Operating margins have expanded from -8.0% to -6.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -15.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 16.9% | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% | 4.4% | 4.6% | -2.5% | 6.5% | 12.7% |
| Operating Margin | -6.8% | -6.8% | 0.6% | -8.0% | -23.0% | -49.0% | -45.7% | -55.6% | -51.2% | -45.2% | -37.9% |
| Net Profit Margin | -7.7% | -7.7% | -0.5% | -10.1% | -25.7% | -52.8% | -49.7% | -55.7% | -50.7% | -45.2% | -37.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -15.3% | -15.3% | -1.8% | -47.7% | -224.5% | -178.0% | -113.4% | -143.4% | -106.7% | -60.4% | -34.4% |
| ROA | -9.1% | -9.1% | -0.9% | -17.1% | -39.2% | -51.7% | -50.6% | -70.5% | -57.7% | -36.5% | -23.2% |
| ROIC | -11.0% | -11.0% | 1.6% | -21.7% | -65.3% | -165.0% | -193.9% | -298.6% | -167.4% | -64.5% | -45.3% |
| ROCE | -10.1% | -10.1% | 1.5% | -20.7% | -59.3% | -65.5% | -58.7% | -95.6% | -72.9% | -42.3% | -26.5% |
RMTI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $16M exceeds total debt of $12M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.34 | 0.34 | 0.42 | 0.63 | 1.16 | 11.40 | 0.70 | 0.20 | — | — | — |
| Debt / EBITDA | — | — | 4.85 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.07 | 0.21 | 0.44 | 6.16 | -0.72 | -0.38 | -0.83 | -0.26 | -0.32 |
| Net Debt / EBITDA | — | — | -0.76 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | -0.67 | — | — | — | — | — | — | — | — |
| Interest Coverage | -4.17 | -4.17 | 0.62 | -2.67 | -8.65 | -12.84 | -15.44 | — | — | — | — |
Net cash position: cash ($16M) exceeds total debt ($12M)
RMTI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Rockwell Medical, Inc.'s current ratio of 3.98x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.63x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.73x to 3.98x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.98 | 3.98 | 2.63 | 1.73 | 2.00 | 1.68 | 5.43 | 2.98 | 3.55 | 5.34 | 7.74 |
| Quick Ratio | 3.63 | 3.63 | 2.22 | 1.38 | 1.67 | 1.49 | 5.12 | 2.69 | 3.24 | 4.51 | 6.54 |
| Cash Ratio | 3.13 | 3.13 | 1.53 | 0.66 | 1.21 | 1.07 | 4.59 | 2.10 | 2.54 | 3.62 | 5.71 |
| Asset Turnover | — | 1.21 | 1.71 | 1.60 | 1.56 | 1.27 | 0.80 | 1.38 | 1.21 | 0.97 | 0.64 |
| Inventory Turnover | 16.81 | 16.81 | 14.54 | 12.76 | 11.82 | 15.79 | 15.20 | 16.03 | 16.09 | 7.02 | 3.83 |
| Days Sales Outstanding | — | 42.91 | 29.82 | 47.59 | 31.38 | 34.85 | 24.48 | 25.02 | 42.33 | 40.48 | 43.79 |
RMTI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Rockwell Medical, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | 5.0% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.8% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.8% | 0.0% |
| Shares Outstanding | — | $36M | $31M | $23M | $10M | $9M | $7M | $6M | $5M | $5M | $5M |
Peer Comparison
Compare RMTI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RMTIYou | $26M | -4.5 | — | — | 16.9% | -6.8% | -15.3% | -11.0% | — |
 NKTR | $1B | -6.8 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 LXRX | $955M | -15.4 | — | — | 99.4% | -98.2% | -39.7% | -22.7% | — |
 SUPN | $3B | -65.4 | 45.2 | 55.7 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 HALO | $8B | 26.9 | 11.3 | 12.7 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 PRGO | $1B | -0.9 | 7.0 | 9.2 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 DVA | $13B | 22.0 | 10.2 | 10.3 | 27.0% | 14.7% | 46.0% | 10.5% | 5.5 |
 FMC | $1B | -0.6 | — | — | 37.0% | -54.4% | -67.8% | -21.2% | — |
 NXST | $5B | 54.7 | 7.0 | 6.7 | 39.0% | 17.4% | 5.0% | 7.4% | 4.2 |
 BAX | $10B | -11.2 | 27.0 | 31.4 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
 BDX | $51B | 24.1 | 13.8 | 19.1 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
| Healthcare Median | — | 22.1 | 14.1 | 18.4 | 63.9% | -4.4% | -33.3% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 29 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
RMTI — Frequently Asked Questions
Quick answers to the most common questions about buying RMTI stock.
What is Rockwell Medical, Inc.'s P/E ratio?
Rockwell Medical, Inc.'s current P/E ratio is -4.5x. The historical average is 157.5x.
What is Rockwell Medical, Inc.'s ROE?
Rockwell Medical, Inc.'s return on equity (ROE) is -15.3%. The historical average is -59.4%.
Is RMTI stock overvalued?
Based on historical data, Rockwell Medical, Inc. is trading at a P/E of -4.5x. Compare with industry peers and growth rates for a complete picture.
What are Rockwell Medical, Inc.'s profit margins?
Rockwell Medical, Inc. has 16.9% gross margin and -6.8% operating margin.